| scholarly article | Q13442814 |
| P2093 | author name string | Yiwei Li | |
| Asfar S Azmi | |||
| Sai-Hong Ignatius Ou | |||
| Ammar Sukari | |||
| Misako Nagasaka | |||
| Mohammed Najeeb Al-Hallak | |||
| P2860 | cites work | Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling | Q24293500 |
| Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes | Q24595981 | ||
| COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer | Q24608391 | ||
| The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation | Q24616946 | ||
| Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance | Q24645668 | ||
| Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity | Q27678097 | ||
| Discovery of Small Molecules that Bind to K‐Ras and Inhibit Sos‐Mediated Activation | Q27678948 | ||
| K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions | Q27680654 | ||
| In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C | Q27684047 | ||
| Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations | Q27700955 | ||
| Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State | Q27703510 | ||
| The GTPase superfamily: conserved structure and molecular mechanism | Q27860524 | ||
| Small-molecule inhibitors of the Rce1p CaaX protease | Q27932239 | ||
| A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene | Q28279136 | ||
| A comprehensive survey of Ras mutations in cancer | Q30416821 | ||
| Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change. | Q34280682 | ||
| Sorafenib inhibits proliferation and invasion in desmoid-derived cells by targeting Ras/MEK/ERK and PI3K/Akt/mTOR pathways | Q53177173 | ||
| Therapeutic strategies to target RAS-mutant cancers | Q57060145 | ||
| Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction | Q61809925 | ||
| Farnesyl Transferase Inhibitors as Potential Anticancer Agents | Q90694429 | ||
| The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients | Q90974072 | ||
| Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. | Q91013491 | ||
| The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity | Q91013772 | ||
| Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience | Q91422133 | ||
| Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study | Q91769678 | ||
| A Potent Isoprenylcysteine Carboxylmethyltransferase (ICMT) Inhibitor Improves Survival in Ras-Driven Acute Myeloid Leukemia | Q92637379 | ||
| AMG 510 First to Inhibit "Undruggable" KRAS | Q92688582 | ||
| Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors | Q92946134 | ||
| Mechanism of activation of a human oncogene | Q34708285 | ||
| Drugging the undruggable RAS: Mission possible? | Q35163434 | ||
| Small-molecule modulation of Ras signaling | Q35188280 | ||
| Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor | Q35207897 | ||
| Rce1 deficiency accelerates the development of K-RAS-induced myeloproliferative disease | Q35615842 | ||
| An orthosteric inhibitor of the Ras-Sos interaction | Q35854216 | ||
| 8-Hydroxyquinoline-based inhibitors of the Rce1 protease disrupt Ras membrane localization in human cells. | Q35878817 | ||
| KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy | Q36545375 | ||
| Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism | Q37113394 | ||
| Farnesyl transferase inhibitor FTI-277 inhibits breast cell invasion and migration by blocking H-Ras activation | Q37205817 | ||
| Isoprenylcysteine carboxylmethyltransferase deficiency exacerbates KRAS-driven pancreatic neoplasia via Notch suppression | Q37259201 | ||
| Dual targeting of PI3K and MEK enhances the radiation response of K-RAS mutated non-small cell lung cancer. | Q37536691 | ||
| KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis. | Q37554470 | ||
| The clinical relevance of KRAS gene mutation in non-small-cell lung cancer | Q38181879 | ||
| Drugging the 'undruggable' cancer targets | Q38667658 | ||
| Structural and functional properties of ras proteins | Q38667916 | ||
| A novel inhibitor of farnesyltransferase with a zinc site recognition moiety and a farnesyl group. | Q38698534 | ||
| PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives | Q38710627 | ||
| Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design | Q38911598 | ||
| Affinity profiling of the cellular kinome for the nucleotide cofactors ATP, ADP, and GTP. | Q39231834 | ||
| AKT/PKB Signaling: Navigating the Network | Q39255027 | ||
| Intrinsic protein disorder in oncogenic KRAS signaling | Q39361391 | ||
| The GDI-like solubilizing factor PDEδ sustains the spatial organization and signalling of Ras family proteins | Q39426327 | ||
| The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma | Q39859156 | ||
| Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance | Q40253550 | ||
| Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor | Q41915120 | ||
| Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer | Q43292375 | ||
| Interaction of GTP derivatives with cellular and oncogenic ras-p21 proteins | Q44953937 | ||
| Ras Binder Induces a Modified Switch-II Pocket in GTP and GDP States | Q46107918 | ||
| EGFR, KRAS, BRAF and HER2 testing in metastatic lung adenocarcinoma: Value of testing on samples with poor specimen adequacy and analysis of discrepancies. | Q47365242 | ||
| Inhibition of Isoprenylcysteine Carboxylmethyltransferase Induces Cell-Cycle Arrest and Apoptosis through p21 and p21-Regulated BNIP3 Induction in Pancreatic Cancer | Q47980483 | ||
| Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor | Q48522303 | ||
| Direct inhibition of RAS: Quest for the Holy Grail? | Q49721819 | ||
| Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model. | Q49952320 | ||
| High-throughput screening identifies small molecules that bind to the RAS:SOS:RAS complex and perturb RAS signaling | Q49997158 | ||
| Atomic structure of the eukaryotic intramembrane RAS methyltransferase ICMT. | Q50001728 | ||
| Targeting the RAS-dependent chemoresistance: The Warburg connection | Q50060608 | ||
| Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer | Q50066241 | ||
| Rce1: mechanism and inhibition | Q50102683 | ||
| P304 | page(s) | 101974 | |
| P577 | publication date | 2020-01-23 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Cancer Treatment Reviews | Q1955762 |
| P1476 | title | KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne? | |
| P478 | volume | 84 |
Search more.